TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01727752

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression
Study: NCT04203134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthguard
Description: The mouthguard is a thin clear acrylic protector fabricated from an impression of a patient's upper teeth and palate. The acrylic protector will be trimmed and will fit onto the patient's upper teeth and palate for use during the day, except when eating to minimize trauma to the tongue that exacerbates burning tongue pain.
Study: NCT03416452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Gait Trainer
Description: standard rolling walker that has a battery operated sensor attached to the side, designed to detect footsteps
Study: NCT00641017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine
Description: Live attenuated Human Parainfluenza Type 1 Virus Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for rHPIVI1 84/del170/942A, Lot PIV1 #104A vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for rHPIVI1 84/del170/942A, Lot PIV1 #104A vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for rHPIVI1 84/del170/942A, Lot PIV1 #104A vaccine
Study: NCT01411917

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transversus abdominis plane block
Description: Ultrasound guidance will be utilized to inject 30ml of 0.375% bupivacaine into the muscular plane between the internal oblique and transversus abdominis muscles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: Ultrasound guidance will be utilized to inject 30ml of 0.375% bupivacaine into the muscular plane between the internal oblique and transversus abdominis muscles.
Study: NCT02815670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Study: NCT03164629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cone-beam CT 3D Emboguide
Description: cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cone-beam CT 3D Emboguide
Description: cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
Study: NCT05164068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information video
Description: The video contents were clear and adapted to the characteristics of the population of Guatemala. The video provided a simple description of the biopsy, its risks and benefits, complications and general recommendations, and was presented preoperatively
Study: NCT01874288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DI-Leu16-IL2
Description: DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DI-Leu16-IL2
Description: DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DI-Leu16-IL2
Description: DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DI-Leu16-IL2
Description: DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DI-Leu16-IL2
Description: DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
Study: NCT04285957

Intervention type: OTHER
Intervention: Questionnaire administration pre test
Description: Pre-test:~Two expert physicians/physical therapist shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI);

Intervention type: OTHER
Intervention: Questionnaire administration - validation
Description: Validation Two expert physicians shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI); In case the patient is unable to be interviewed due to aphasia cognitive or sensorial problems, a proxy would be interviewed both at T0 and at T1 (the same proxy would be interviewed both times)
Study: NCT01692457

Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Golimumab will be administered as per the recommended doses. Golimumab 50 mg will be given as a subcutaneous injection once a month, on the same date each month. For rheumatoid arthritis: Golimumab 2 mg/kg will be given as a 30 minute intravenous infusion at Weeks 0 and 4, then every 8 weeks thereafter.
Study: NCT01396434

Intervention type: BIOLOGICAL
Intervention: Prevenar 13
Description: Prevenar 13 vaccine as prescribed by the physician based on approved product indication
Study: NCT01776710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured education
Description: The structured education intervention will comprise a 3-hour education workshop delivered by two trained facilitators and a follow-up telephone call 2 weeks later. The aims of the education programme are to enhance patients' understanding of peripheral arterial disease and intermittent claudication, and to support patients in increasing their daily walking activity. Key behaviour change techniques that will be incorporated will include goal setting, action planning, barrier identification/problem solving, prompt review of behavioural goals, prompt self-monitoring of behaviour, and instructions on how to perform the behaviour.
Study: NCT01744301

Intervention type: DRUG
Intervention: Risk of seizure
Description: Patients newly prescribed PPI and H2RA, respectively

Intervention type: DRUG
Intervention: Risk of seizure
Description: Patients newly prescribed PPI and H2RA, respectively
Study: NCT02566681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC construct for Osteonecrosis
Description: 30 days before implanting the construct made with MSC + TP + DBM, bone marrow of patients diagnosed with osteonecrosis of the jaw included in the clinical trial is obtained. The bone marrow will be obtained according to standard practice for Hematologists of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).~Mononuclear bone marrow cells were separated and cultured in GMP conditions (Good Manufacturing Practices). The cells are seeded on tricalcium phosphate and maintained in culture for 14 days.~The day when the implant is performed, the patient is prepared in the operating room. The area where the implant will be placed is cleaned. Mesenchymal cells seeded in tricalcium phosphate are mixed with demineralized bone matrix and It's coagulated with autologous platelet rich plasma and grafting is performed. Finally, the oral mucosa or skin will be sealingly closed by silk sutures.
Study: NCT00994812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: The obese women will be randomized either to metformin (2g/day) or to placebo, and the non-obese either to metformin (1.5g/day) or to placebo. All subjects will be evaluated 1 to 7 days after spontaneous menstruation (oligomenorrheic patients), or at any other convenient time (amenorrheic subjects). After the treatment of 3 months with metformin/placebo alone, another appropriate infertility treatment will be combined with metformin/placebo (clomiphene, ovulation induction, insemination or in vitro fertilization) if no pregnancy has occurred. This treatment will be continued another 6 months' period. If pregnancy occurs, subjects will be re-examined at 7-8 weeks of gestation.
Study: NCT03399071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOT-A
Description: This is a single-arm study with all patients receiving combination FLOT-A
Study: NCT03691766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation Therapy
Description: Photobiomodulation therapy, a mix of red lights thought to improve mitochondrial function will be applied in and acute and chronic manner to test whether muscle fatigue improves in persons with MS.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Device with sham light source
Study: NCT03409354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation
Description: There are five different categories of exercise in the rehabilitation program, which combines both physiotherapy (Category 1 to 4) and occupational therapy components (Category 5). Each tele-therapy session could cover all five categories of exercises. Progression of levels within each exercise within each category should be determined by the tele-therapist and in consultation with the participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual rehabilitation care (e.g., PT, OT and ST), prescribed by rehabilitation therapists at participating centers and performed by participants at participating centers.
Study: NCT03567928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sedation with Gastro Cuff Pilot Laryngeal Mask
Description: This specific type of laryngeal mask allows to separate the gastric and respiratory tract and allows the anesthesiologist to support patient's ventilation as (and only if) necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Target controlled infusion (TCI) with propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Target controlled infusion (TCI) with propofol
Study: NCT02912182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: Betamethasone intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: Betamethasone intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous NaCl intravenous administration Placebo tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral tablets
Study: NCT01433055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Minocycline Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day (minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day(minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition.
Study: NCT00699426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nexium
Description: 40 mg once daily is tested together with Yoghurt

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nexium
Description: nexium and placebo are tested

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yoghurt
Description: Yoghurt

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo+placebo
Description: placebo and placebo are tested.
Study: NCT03406754

Intervention type: BEHAVIORAL
Intervention: rehabilitation programs
Description: an 8-week multidisciplinary inpatient rehabilitation program
Study: NCT00533286

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: benzodiacepine
Description: diazepam (2 x 5 mg/ die)
Study: NCT00817167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inReach bronchoscopy planning software
Description: inReach planning software creates three-dimensional lung CT reconstruction, enabling rapid virtual endoscopic depiction of the airways that allows to plan bronchoscopy virtually.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard lung CT viewer
Description: CT viewer, used for standard bronchoscopy
Study: NCT01230931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitagel
Description: Vitagel (by Stryker) is a topical surgical hemostat spray that results in coagulation. The components are as follows: autogenous blood is drawn and centrifuged to produce a sample of platelets and growth factors; this is combined with a bovine thrombin and collagen solution. When the two are applied together, it produces the hemostatic effect.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care for hemostasis in acetabular surgery includes electrocautery/ligation of bleeding vessels, fracture reduction and stabilization, cell-saver, lap packing.
Study: NCT04279041

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root canal preparation
Description: root canal preparation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: root canal preparation
Description: root canal preparation
Study: NCT01809717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Lifting Exercises
Study: NCT02187718

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sentinel Node Procedure under Local Anaesthesia

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sentinel Node Procedure under General Anaesthesia
Study: NCT03200041

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Description: 20 ml blood sample taken from vein in arm

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Description: 20 ml blood sample taken from vein in arm
Study: NCT00749866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin
Description: Nebulised 80mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Nebulised 4mls 0.9% Saline twice daily
Study: NCT03547219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Study: NCT03258710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: Tenofovir Disoproxil Fumarate is a nucleos(t)ide analogue that inhibits HBV growth. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.
Study: NCT01623518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-NP+M1
Description: Dose escalation in a 3+3 study plan;~5 x10\^8 vp, 5 x10\^9 vp, 2.5 x10\^10 vp, 5 x10\^10 vp
Study: NCT00804323

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patter Scan Laser System (OptiMedica, Santa Clara, CA, USA)
Description: Pattern Scan Laser trabeculoplasty
Study: NCT02449005

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM-MSCs/fibrin glue/collagen fleece
Description: Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fibrin glue/collagen fleece
Description: The biocomplex of autologous fibrin glue and collagen fleece devoid of stem cells will fill the osseous defect

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement
Description: Group C will receive minimally invasive surgery employing papilla preservation techniques in addition to retaining the soft tissue wall of the pocket. There will be no use of grafting materials
Study: NCT03456557

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Perfusion computed tomography.
Description: Using specific post treatment imaging software ( Olea® ) we will calculatell permeability parameters : the pancreatic blood flow and the k-trans, capillary membrane permeability factor.
Study: NCT01787019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral feeding

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral feeding
Study: NCT01501019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Sjöegren arm: 30-60 minutes of combined aerobic and strength exercises, twice a week, moderate intensity.~Myositis arm: 30 minutes of resistance training combined partial blood flow restriction, twice a week, low intensity.~Takayasu's arteritis arm: 30-50 minutes of aerobic, twice a week, moderate intensity.
Study: NCT04410406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Ivermectin (IVM) 200 µg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Ivermectin (IVM) 200 µg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diethylcarbamazine
Description: Diethylcarbamazine (DEC) 6mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diethylcarbamazine
Description: Diethylcarbamazine (DEC) 6mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole (ABZ) 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole (ABZ) 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole (ABZ) 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole (ABZ) 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxidectin
Description: Moxidectin (Mox) 8 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxidectin
Description: Moxidectin (Mox) 8 mg
Study: NCT02577016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 50 mg tablet administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to sitagliptin administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipragliflozin
Description: 50 mg tablet administered orally as background medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Description: 50 mg tablet administered orally as background medication
Study: NCT01601665

Intervention type: DEVICE
Intervention: SN6AT6 Intraocular Lens
Description: Acrylic intraocular lens with cylinder power at the IOL plane of 3.75 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.

Intervention type: DEVICE
Intervention: SN6AT7 Intraocular Lens
Description: Acrylic intraocular lens with cylinder power at the IOL plane of 4.50 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.

Intervention type: DEVICE
Intervention: SN6AT8 Intraocular Lens
Description: Acrylic intraocular lens with cylinder power at the IOL plane of 5.25 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.

Intervention type: DEVICE
Intervention: SN6AT9 Intraocular Lens
Description: Acrylic intraocular lens with cylinder power at the IOL plane of 6.00 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.

Intervention type: DEVICE
Intervention: SN60WF Intraocular Lens
Description: Acrylic aspheric monofocal intraocular lens. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
Study: NCT00533286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benzodiacepine
Description: diazepam (2 x 5 mg/ die)
Study: NCT03410056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin alfa
Description: Efavaleukin alfa administered as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin alfa
Description: Efavaleukin alfa administered as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin alfa
Description: Efavaleukin alfa administered as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin alfa
Description: Efavaleukin alfa administered as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin alfa
Description: Efavaleukin alfa administered as a subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as a subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as a subcutaneous injection.